Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.
17,52USD
−9,36% (−1,81)
Tänään 
Ylin19,38
Alin17,50
Vaihto
389,7 MUSD
17,52USD
−9,36% (−1,81)
Tänään 
Ylin19,38
Alin17,50
Vaihto
389,7 MUSD
17,52USD
−9,36% (−1,81)
Tänään 
Ylin19,38
Alin17,50
Vaihto
389,7 MUSD
17,52USD
−9,36% (−1,81)
Tänään 
Ylin19,38
Alin17,50
Vaihto
389,7 MUSD
17,52USD
−9,36% (−1,81)
Tänään 
Ylin19,38
Alin17,50
Vaihto
389,7 MUSD
17,52USD
−9,36% (−1,81)
Tänään 
Ylin19,38
Alin17,50
Vaihto
389,7 MUSD
2025 Q3 -tulosraportti
99 päivää sitten

Tarjoustasot

Määrä
Osto
2 836
Myynti
Määrä
484

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----
Ylin
19,38
VWAP
18,35
Alin
17,5
VaihtoMäärä
389,7 36 254 392
VWAP
18,35
Ylin
19,38
Alin
17,5
VaihtoMäärä
389,7 36 254 392

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2025 Q4 -tulosraportti
23.2.
Menneet tapahtumat
2025 Q3 -tulosraportti
3.11.2025
2025 Q2 -tulosraportti
4.8.2025
Vuosittainen yhtiökokous 2025
12.6.2025
2025 Q1 -tulosraportti
5.5.2025
2024 Q4 -tulosraportti
24.2.2025

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 51 min sitten
    ·
    51 min sitten
    ·
    I really hope they get such a beating in the upcoming lawsuit with Novo that they realize they shouldn't freeload on others, really good if they are sentenced to pay back so much that they go bankrupt, yes, you guessed right, I myself have shares in Novo Nordisk
  • 2 t sitten
    ·
    2 t sitten
    ·
    What do you think about the future here? I'm 65% in the red and don't know what to do.
    1 t sitten
    ·
    1 t sitten
    ·
    Focus on what the company does, all that happens in the news is just «mr.market» having some mood swings. Marcet cap slightly over 3 billion, earned 1.5 billion last year, still growing a lot in customer numbers and revenue despite the glp-styret. Recently launched labs seem promising, cancer-tests that are making progress. I have bought a bit more, but not much. Just took advantage of the sale. Don't let emotions make the buys and sells 🤝
    15 min sitten
    ·
    15 min sitten
    ·
    I think you should read their financial statements - they have not earned 1.5 billion, neither last year nor all years combined since the company was founded. They had a revenue of approx. 1.5 billion last year. Their earnings measured against revenue are extremely low.
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    I own shares in HIMS, and it's no secret here that I am extremely bullish on the company. Therefore, in light of Novo's lawsuit, I have made a video about why I have bought more HIMS. https://www.youtube.com/watch?v=FUikNVIdoW8
    2 t sitten
    ·
    2 t sitten
    ·
    But the management is good, because they copy a patented product and sell it for 1/3 of the price?.... In my world, it fits reasonably well that Hims must be considered lazy or incompetent, as they either don't care about the law or have no knowledge of what a patent is? If you look at key figures for Hims, it certainly doesn't show that the company is being traded as if they are about to go bankrupt. They are traded based on the uncertainty of what economic consequences it might have for Hims when they are sued. Being sued is, of course, not something an investor or company is interested in. Regarding whether the management is incompetent, it must be said that there is a fair assessment here that they are. Why else make a big announcement that you are offering the Wegovy pill for 49 dollars per month, and 2 days later remove the product. So, laziness and/or lack of knowledge must be said to be present in the management, no matter how you look at it. Personally, I have written previously that I would not be surprised if the company does not exist within the next 5 years, precisely because of the management's actions and the way their business is run - if they want to survive, they must sell patent-protected medicine via agreements with e.g. Novo, Lilly and others. Or they must sell medicine that has gone off patent. This is, of course, just my own opinion and view :)
    40 min sitten
    ·
    40 min sitten
    ·
    Hope they go bankrupt
  • 4 t sitten
    ·
    4 t sitten
    ·
    It's probably just going to be smashed.
    3 t sitten
    ·
    3 t sitten
    ·
    If one does not wish to comply with the legislation : (( then there is probably only a fine and punishment left certainly self-inflicted when one freeloads off other COMPANIES .
  • 11 t sitten
    11 t sitten
    Thinking to buy at 10 to 15 range any suggestions? Thanks in advance
    6 t sitten · Muokattu
    ·
    6 t sitten · Muokattu
    ·
    "Lose money for the firm, and I will be understanding. Lose a shred of reputation for the firm, and I will be ruthless". - Buffet The company's reputation has taken a hit, but it will not go bankrupt and it continues to make money. If you have a long-term perspective, it could be a good opportunity.
    5 t sitten
    5 t sitten
    I’m thinking to short term just the boost as usual in stock
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q3 -tulosraportti
99 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 51 min sitten
    ·
    51 min sitten
    ·
    I really hope they get such a beating in the upcoming lawsuit with Novo that they realize they shouldn't freeload on others, really good if they are sentenced to pay back so much that they go bankrupt, yes, you guessed right, I myself have shares in Novo Nordisk
  • 2 t sitten
    ·
    2 t sitten
    ·
    What do you think about the future here? I'm 65% in the red and don't know what to do.
    1 t sitten
    ·
    1 t sitten
    ·
    Focus on what the company does, all that happens in the news is just «mr.market» having some mood swings. Marcet cap slightly over 3 billion, earned 1.5 billion last year, still growing a lot in customer numbers and revenue despite the glp-styret. Recently launched labs seem promising, cancer-tests that are making progress. I have bought a bit more, but not much. Just took advantage of the sale. Don't let emotions make the buys and sells 🤝
    15 min sitten
    ·
    15 min sitten
    ·
    I think you should read their financial statements - they have not earned 1.5 billion, neither last year nor all years combined since the company was founded. They had a revenue of approx. 1.5 billion last year. Their earnings measured against revenue are extremely low.
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    I own shares in HIMS, and it's no secret here that I am extremely bullish on the company. Therefore, in light of Novo's lawsuit, I have made a video about why I have bought more HIMS. https://www.youtube.com/watch?v=FUikNVIdoW8
    2 t sitten
    ·
    2 t sitten
    ·
    But the management is good, because they copy a patented product and sell it for 1/3 of the price?.... In my world, it fits reasonably well that Hims must be considered lazy or incompetent, as they either don't care about the law or have no knowledge of what a patent is? If you look at key figures for Hims, it certainly doesn't show that the company is being traded as if they are about to go bankrupt. They are traded based on the uncertainty of what economic consequences it might have for Hims when they are sued. Being sued is, of course, not something an investor or company is interested in. Regarding whether the management is incompetent, it must be said that there is a fair assessment here that they are. Why else make a big announcement that you are offering the Wegovy pill for 49 dollars per month, and 2 days later remove the product. So, laziness and/or lack of knowledge must be said to be present in the management, no matter how you look at it. Personally, I have written previously that I would not be surprised if the company does not exist within the next 5 years, precisely because of the management's actions and the way their business is run - if they want to survive, they must sell patent-protected medicine via agreements with e.g. Novo, Lilly and others. Or they must sell medicine that has gone off patent. This is, of course, just my own opinion and view :)
    40 min sitten
    ·
    40 min sitten
    ·
    Hope they go bankrupt
  • 4 t sitten
    ·
    4 t sitten
    ·
    It's probably just going to be smashed.
    3 t sitten
    ·
    3 t sitten
    ·
    If one does not wish to comply with the legislation : (( then there is probably only a fine and punishment left certainly self-inflicted when one freeloads off other COMPANIES .
  • 11 t sitten
    11 t sitten
    Thinking to buy at 10 to 15 range any suggestions? Thanks in advance
    6 t sitten · Muokattu
    ·
    6 t sitten · Muokattu
    ·
    "Lose money for the firm, and I will be understanding. Lose a shred of reputation for the firm, and I will be ruthless". - Buffet The company's reputation has taken a hit, but it will not go bankrupt and it continues to make money. If you have a long-term perspective, it could be a good opportunity.
    5 t sitten
    5 t sitten
    I’m thinking to short term just the boost as usual in stock
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
2 836
Myynti
Määrä
484

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----
Ylin
19,38
VWAP
18,35
Alin
17,5
VaihtoMäärä
389,7 36 254 392
VWAP
18,35
Ylin
19,38
Alin
17,5
VaihtoMäärä
389,7 36 254 392

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2025 Q4 -tulosraportti
23.2.
Menneet tapahtumat
2025 Q3 -tulosraportti
3.11.2025
2025 Q2 -tulosraportti
4.8.2025
Vuosittainen yhtiökokous 2025
12.6.2025
2025 Q1 -tulosraportti
5.5.2025
2024 Q4 -tulosraportti
24.2.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q3 -tulosraportti
99 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2025 Q4 -tulosraportti
23.2.
Menneet tapahtumat
2025 Q3 -tulosraportti
3.11.2025
2025 Q2 -tulosraportti
4.8.2025
Vuosittainen yhtiökokous 2025
12.6.2025
2025 Q1 -tulosraportti
5.5.2025
2024 Q4 -tulosraportti
24.2.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
  • 51 min sitten
    ·
    51 min sitten
    ·
    I really hope they get such a beating in the upcoming lawsuit with Novo that they realize they shouldn't freeload on others, really good if they are sentenced to pay back so much that they go bankrupt, yes, you guessed right, I myself have shares in Novo Nordisk
  • 2 t sitten
    ·
    2 t sitten
    ·
    What do you think about the future here? I'm 65% in the red and don't know what to do.
    1 t sitten
    ·
    1 t sitten
    ·
    Focus on what the company does, all that happens in the news is just «mr.market» having some mood swings. Marcet cap slightly over 3 billion, earned 1.5 billion last year, still growing a lot in customer numbers and revenue despite the glp-styret. Recently launched labs seem promising, cancer-tests that are making progress. I have bought a bit more, but not much. Just took advantage of the sale. Don't let emotions make the buys and sells 🤝
    15 min sitten
    ·
    15 min sitten
    ·
    I think you should read their financial statements - they have not earned 1.5 billion, neither last year nor all years combined since the company was founded. They had a revenue of approx. 1.5 billion last year. Their earnings measured against revenue are extremely low.
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    I own shares in HIMS, and it's no secret here that I am extremely bullish on the company. Therefore, in light of Novo's lawsuit, I have made a video about why I have bought more HIMS. https://www.youtube.com/watch?v=FUikNVIdoW8
    2 t sitten
    ·
    2 t sitten
    ·
    But the management is good, because they copy a patented product and sell it for 1/3 of the price?.... In my world, it fits reasonably well that Hims must be considered lazy or incompetent, as they either don't care about the law or have no knowledge of what a patent is? If you look at key figures for Hims, it certainly doesn't show that the company is being traded as if they are about to go bankrupt. They are traded based on the uncertainty of what economic consequences it might have for Hims when they are sued. Being sued is, of course, not something an investor or company is interested in. Regarding whether the management is incompetent, it must be said that there is a fair assessment here that they are. Why else make a big announcement that you are offering the Wegovy pill for 49 dollars per month, and 2 days later remove the product. So, laziness and/or lack of knowledge must be said to be present in the management, no matter how you look at it. Personally, I have written previously that I would not be surprised if the company does not exist within the next 5 years, precisely because of the management's actions and the way their business is run - if they want to survive, they must sell patent-protected medicine via agreements with e.g. Novo, Lilly and others. Or they must sell medicine that has gone off patent. This is, of course, just my own opinion and view :)
    40 min sitten
    ·
    40 min sitten
    ·
    Hope they go bankrupt
  • 4 t sitten
    ·
    4 t sitten
    ·
    It's probably just going to be smashed.
    3 t sitten
    ·
    3 t sitten
    ·
    If one does not wish to comply with the legislation : (( then there is probably only a fine and punishment left certainly self-inflicted when one freeloads off other COMPANIES .
  • 11 t sitten
    11 t sitten
    Thinking to buy at 10 to 15 range any suggestions? Thanks in advance
    6 t sitten · Muokattu
    ·
    6 t sitten · Muokattu
    ·
    "Lose money for the firm, and I will be understanding. Lose a shred of reputation for the firm, and I will be ruthless". - Buffet The company's reputation has taken a hit, but it will not go bankrupt and it continues to make money. If you have a long-term perspective, it could be a good opportunity.
    5 t sitten
    5 t sitten
    I’m thinking to short term just the boost as usual in stock
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
2 836
Myynti
Määrä
484

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----
Ylin
19,38
VWAP
18,35
Alin
17,5
VaihtoMäärä
389,7 36 254 392
VWAP
18,35
Ylin
19,38
Alin
17,5
VaihtoMäärä
389,7 36 254 392

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt